Alex Zhavoronkov, Insilico Medicine CEO
Insilico Medicine, an early force in AI-driven drug R&D, lets IPO plans peter out for second year in a row
One of the original AI-driven drug discovery and development biotechs has let its plans to list on the Hong Kong stock exchange lapse for the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
